**
Recent disclosures from the Environmental Protection Agency (EPA) have unveiled significant meetings between top officials and Bayer’s CEO, Bill Anderson, sparking concerns about the influence of corporate interests on regulatory decisions. These interactions occurred in the lead-up to critical litigation regarding glyphosate, the active ingredient in Bayer’s controversial herbicide, Roundup, which has been linked to cancer in numerous lawsuits.
Key Meeting Highlights Corporate Influence
On 17 June 2025, a meeting took place at the EPA involving Anderson and other Bayer executives, alongside high-ranking agency officials, including Lee Zeldin, the agency’s administrator. According to internal records, the agenda included discussions around “litigation” issues and potential Supreme Court actions concerning glyphosate. This meeting occurred just months before the Trump administration took steps to bolster Bayer’s position in ongoing legal battles, including a forthcoming Supreme Court review of the company’s liability claims.
Bayer has faced a barrage of lawsuits from thousands of individuals alleging that they developed cancer due to prolonged exposure to glyphosate-based products. Central to these claims is the assertion that Bayer failed to adequately inform users about the potential cancer risks associated with its herbicides. The company argues that if the EPA does not mandate cancer warnings on glyphosate products, it should not be held accountable for failing to issue such warnings.
Regulatory Landscape Under Scrutiny
The meeting with Bayer’s executives is emblematic of broader concerns regarding the relationship between the EPA and powerful agribusiness interests. Critics, including Nathan Donley from the Center for Biological Diversity, have expressed alarm over what they perceive as a prioritisation of corporate profits over public health. “When the CEO of one of the largest companies in the world meets with political appointees in a US regulatory office, it underscores the disproportionate influence corporations exert on health-related decisions,” Donley remarked, reflecting widespread unease about the integrity of the regulatory process.
Bayer has maintained that such meetings are standard procedure within the regulatory framework, asserting their transparency regarding litigation matters. An EPA spokesperson described the meeting as a routine introductory session and denied that it focused on pending litigation, despite planning documents indicating otherwise.
Government Actions Following the Meeting
In the months following the June meeting, the Trump administration’s support for Bayer became increasingly evident. A notable development occurred in December 2025, when D. John Sauer, the solicitor general appointed by the Trump administration, submitted a filing to the Supreme Court advocating for Bayer’s case. This led to the court agreeing to hear the matter, with a hearing scheduled for 27 April 2026.
On 18 February 2026, the White House took further action by invoking the Defense Production Act to ensure the continued production of glyphosate herbicides, effectively providing immunity to manufacturers like Bayer. In early March, Sauer filed an amicus brief supporting Bayer’s position, further solidifying the administration’s commitment to assisting the company amid ongoing litigation.
Concerns Over Regulatory Integrity
Legal experts and advocates have raised alarms over the implications of these meetings and the subsequent actions taken by the administration. Whitney Di Bona, a consumer safety advocate, articulated a pressing concern: “It is troubling that the CEO of a major pesticide company can engage in private discussions with the EPA regarding limiting the company’s liability. The agency must also consider the voices of those affected, including individuals who claim to have suffered health consequences from using Roundup.”
Critics contend that the preferential access enjoyed by corporate leaders to regulatory officials starkly contrasts with the experiences of everyday citizens seeking to voice their concerns about product safety. Naomi Oreskes, a Harvard professor focused on corporate influence in regulation, noted that the pattern of industry leaders having privileged access to government officials raises significant ethical questions about the regulatory process.
Zen Honeycutt, founder of Moms Across America, echoed these sentiments, stating that the coercive influence of chemical companies on regulatory agencies is not a new phenomenon. Despite their attempts to engage with the EPA, advocacy groups have often found that their concerns go unaddressed.
Why it Matters
The revelations surrounding the meeting between Bayer executives and EPA officials underscore a growing concern regarding the intersection of corporate power and public health policy. As litigation over glyphosate continues, the potential for corporate interests to shape regulatory outcomes raises critical questions about the integrity of the EPA and its commitment to safeguarding public health. The implications of these interactions extend beyond Bayer, potentially setting a precedent for how corporate influence can dictate the terms of health and safety regulations in the future.
